Form 8-K - Current report:
SEC Accession No. 0001213900-15-004311
Filing Date
2015-06-05
Accepted
2015-06-05 14:58:11
Documents
7
Period of Report
2015-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k060415_actiniumpharma.htm 8-K 23017
2 OPINION OF BARCLAY DAMON LLP. f8k060415ex5i_actinium.htm EX-5.1 8669
3 PLACEMENT AGENT AGREEMENT, DATED JUNE 4, 2015, BY AND BETWEEN ACTINIUM PHARMACEU f8k060415ex10i_actinium.htm EX-10.1 197915
4 FORM OF SUBSCRIPTION AGREEMENT, DATED JUNE 4, 2015, BY AND AMONG ACTINIUM PHARMA f8k060415ex10ii_actinium.htm EX-10.2 92072
5 PRESS RELEASE, DATED JUNE 4, 2015 f8k060415ex99i_actinium.htm EX-99.1 10582
6 GRAPHIC imagex5i.jpg GRAPHIC 2251
7 GRAPHIC img_001.jpg GRAPHIC 7050
  Complete submission text file 0001213900-15-004311.txt   346551
Mailing Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 15915643
SIC: 2834 Pharmaceutical Preparations